Breathe Well Live Well
 FierceBiotech IT |
10 Big Pharma smartphone apps
FierceBiotech IT Weather, pollen levels and pollution can wreak havoc on a person with asthma. But GlaxoSmithKline's MyAsthma app, available only in the U.K. so far, gives those suffering from the affliction the option to keep tabs on those elements and potentially … |
View full post on asthma – Google News
 World First Travel Insurance |
GSK asthma drug cuts symptoms 52%; ready for PhIII
Pharma Times GlaxoSmithKline's mepolizumab is now ready for late-stage testing after turning in a strong performance in Phase II trials assessing the experimental drug in a rare and hard-to-treat form of asthma. The Phase IIb trial was designed to investigate … GSK drug halves attacks in hard-to-treat asthma Drug 'could cut asthma A&E visits' Experimental Asthma Drug Halves Attacks |
View full post on asthma – Google News
 Zee News |
Aurobindo Pharma, Glenmark get USFDA nod for generic asthma drug
Economic Times NEW DELHI: Drug firms Aurobindo Pharma and Glenmark today said they have received approval from the US health regulator to manufacture and market generic montelukast sodium tablets used for treating asthma and allergies. Both the companies said … Pharma cos set to gain from US nod for asthma drug |
View full post on asthma – Google News
|
Pharma cos set to gain from US nod for asthma drug
Business Standard New Delhi, Aug 5 (PTI) Indian drug makers, including Aurobindo and Glenmark, are set to benefit from a decision by the USFDA to allow sale of generic Singulair tablets used for treating asthma and allergies in the US market. Last week the US Food and … |
View full post on asthma – Google News
|
Indian pharma companies like Aurobindo and Glenmark set to gain from USFDA …
Economic Times NEW DELHI: Indian drug makers, including Aurobindo and Glenmark, are set to benefit from a decision by the USFDA to allow sale of generic Singulair tablets used for treating asthma and allergies in the US market. Last week the US Food and Drug … |
View full post on asthma – Google News
|
GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with …
The Pharma Letter Asthma (100/25mcg and 200/25mcg): The regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate. • COPD (100/25mcg): The … GSK, Theravance seek approvals for FF/VI in US, Europe GSK and Theravance file next-generation Advair in USA, EU |
View full post on asthma – Google News
|
Global asthma and COPD drug market to reach nearly $27 billion in …
The Pharma Letter The global asthma and chronic obstructive pulmonary disease (COPD) market was worth $25.102 billion in 2010, and is expected to reach $26.965 billion in … |
View full post on asthma – Google News
|
MediciNova shares plunge as asthma drug fails in Ph IIb trial
The Pharma Letter MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … |
View full post on asthma – Google News
 Packaging Europe |
Aptar Pharma celebrates asthma day with a twister™ of innovation
Packaging Europe World leader in the development and manufacturing of nasal and pulmonary drug delivery devices including inhalers for asthma, Aptar Pharma launches Twister™, a new versatile affordable capsule-based Dry Powder Inhaler (DPI) specifically targeting fast … |
View full post on asthma – Google News
|
Actelion ends development of asthma and SAR drug
Pharma Times Actelion has suffered a pipeline setback with the failure of its asthma and seasonal allergic rhinitis drug setipiprant in a mid-stage and a late-stage trial. The Swiss biotech says that it will "re-direct its development efforts in the … |
View full post on asthma – Google News